ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA
Reports Recent Business Progress and First Quarter 2026 Financial Results
License Agreement with Xiamen Amoytop for Hepatitis B Treatment
Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
Financial Results, Press Release
Nikhil Aneja Appointed Principal Accounting Officer at Aligos Therapeutics
Reports Recent Business Progress and Third Quarter 2025 Financial Results
News, Articles of Incorporation, Material Contracts
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence